Product Pipeline

Today, Parkinson’s disease care depends on clinical observation, which can be subjective and time-consuming. ANLIVA® Eye Movement aims to use eye-tracking sensors for fast, objective assessments of treatment response. Our goal is to enhance clinical decision-making with digital biomarkers to support evaluation and tracking of disease progression.

Clinical trials in collaboration with Dartmouth-Hitchcock Clinic (USA) are underway, with FDA 510(k) clearance targeted for the end of 2025. Potential for early detection. Patent pending.

Deep Brain Stimulation (DBS) is a well-established therapy for late-stage Parkinson’s disease. Calibrating DBS settings can be both complex and time-consuming. ANLIVA® Deep Brain Stimulation aims for optimizing signal programming. Our solution creates a digital twin of the patients brain to predict treatment response and suggest optimal settings.

Clinical trials in collaboration with Dartmouth-Hitchcock Clinic (USA) are underway, with FDA 510(k) clearance targeted for the end of 2026. DBS vendor-agnostic solution. Patent pending.

Autism diagnosis depends on subjective tests and behavior observations. Misdiagnoses and missed signs are common, especially in young children and adults. Psilmi aims for earlier, more precise diagnosis and intervention for individuals who are difficult to assess. Our goal is to differentiate autism from other conditions through automatic analysis of multiple biomarkers captured via eye-tracking.

Co-development with Uppsala University (Sweden) for FDA 510(k) US market clearance. Pilot study accuracy is state-of-the art. Potential for expansion into more neuropsychiatric conditions.